TrialPath
Recruiting

Mitochondrial Function and Metabolomic Profile in Alzheimer's Disease and Related Dementias

NCT06880406 · Centre Hospitalier Universitaire de Nice
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Early Alterations of Peripheral Mitochondrial Function and Metabolomic Profile in Patients With Alzheimer's Disease and Related Dementias
About this study
Study will be proposed to the patient of the Nice Memory center who had a lumbar puncture and who agreed on the storage of a sample of their cerebrospinal fluid. Two groups of patients will be compared: the Alzheimer"s disease patient with positive amyloid on the cerebrospinal fluid and the non Alzheimer patient with negative amyloid on the cerebrospinal fluid. there will also be a group of healthy volonteer with one blood sample Blood samples will be collected at inclusion and one year to obtain the mitochondrial metabolomic signature
Eligibility criteria
Inclusion Criteria: * Neurocognitive disorder with spontaneous complaint or reported for at least 6 months * Diagnostic process according to current Haute Autorité de Santé (HAS) recommendations. * cerebrospinal fluid biomarker dosage done within the study center and agreement to bio-collection of residual cerebrospinal fluid * Patient having agreed to sign the informed consent * Patient affiliated or beneficiary of a social security scheme For alzheimer group : diagnosis of Alzheimer's disease according to NIA-AA 2024 criteria (presence of a pathogenic amyloid process in the cerebrospinal fluid) For non alzheimer group : diagnosis of mild or major neurocognitive disorder according to Manuel diagnostique et statistique des troubles mentaux edition 5 (DSM-V) criteria, not linked to Alzheimer's disease (absence of pathogenic amyloid process in the cerebrospinal fluid) For healthy volonteers: * Adult patients * No history of neurological or psychiatric disorders * No complaints of memory problems or cognitive impairment * Mini-Mental State Examination (MMSE) score ≥ 27/30 * Clinical Dementia Rating - Sum of Boxes (CDR-SOB) equal to 0 * Patient affiliated with or covered by a social security scheme Exclusion Criteria: \- Vulnerable people
Study design
Enrollment target: 250 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-07-01
Estimated completion: 2029-04-01
Last updated: 2026-06-18
Interventions
Other: MMSE and blood draw
Primary outcomes
  • • Mitochondrial oxygen consumption of peripheral blood cells (At Baseline)
  • • Mitochondrial oxygen consumption of peripheral blood cells (At 1 year)
Sponsor
Centre Hospitalier Universitaire de Nice · other
Contacts & investigators
ContactJustine Lemaire · contact · lemaire.j@chu-nice.fr · 33492034778
InvestigatorAurélie MOUTON, MD,PhD · principal_investigator, Centre Hospitalier Universitaire de Nice
All locations (1)
CHU de NiceRecruiting
Nice, PACA, France
Mitochondrial Function and Metabolomic Profile in Alzheimer's Disease and Related Dementias · TrialPath